We are a provider of automotive financing facilitation and management services targeting existing and prospective ridesharing drivers. We also operate an online P2P lending platform providing loan matching services connecting investors with individual and small-to-medium-sized enterprise borrowers. Our operations are based in Chengdu, the center of southwest China and focus on servicing our customers […]

  We are a biopharmaceutical company utilizing our differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, our approach relies on the human immune system to direct us to unique antibody-target pairs from […]

  We are a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. We founded BridgeBio in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, […]

  We are a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. We are applying a precision medicine approach to neurodegeneration by studying our gene therapies in genetically defined patient populations. We believe this will increase the probability […]

We are a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. We designed our NeXT Platform to adapt to the complex and evolving understanding of cancer, providing our biopharmaceutical customers with information on all of the approximately 20,000 human genes, […]

  We are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. We are developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near […]

  We are a newly formed, self-administered and self-managed real estate investment company focused on acquiring, improving, owning and managing multi-tenant office properties in high-growth urban nodes in the Midwest and Southeast United States within target markets, which we define as MSAs, other than the major markets, that have populations of at least one million […]

  We are a leading general ELT service provider in China. We are committed to improving the overall English competence and practical skills of the general Chinese population. According to the Frost & Sullivan Report, we are the second largest player in China’s offline general ELT market, which comprised approximately 74.1% of the general ELT market […]

  We intend to focus our efforts on acquiring an operating company in the health food and supplement sector, although our efforts in identifying a prospective target business will not be limited to a particular industry. Our efforts in identifying prospective target businesses will not be limited to a particular geographic region, although we intend […]

  We are a newly organized blank check company formed as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We intend to acquire and […]